Exagen(XGN) Stock Price Today | Quotes & News

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Major Shareholder Sells Off Huge Chunk of Exagen Stock!
TipRanksMar 27 22:01 ET
BTIG Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsMar 12 16:32 ET · Ratings
CCORF Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $7
Moomoo NewsMar 12 16:32 ET · Ratings
William Blair Initiates Exagen(XGN.US) With Buy Rating
Moomoo NewsMar 12 16:32 ET · Ratings
Exagen (XGN) Gets a Buy From Canaccord Genuity
TipRanksMar 12 07:17 ET · Ratings
Exagen's Positive Outlook: Buy Rating Backed by Strong Performance and Growth Potential
TipRanksMar 12 05:17 ET · Ratings

Comments

4

Jaguar8

Jan 13 06:02

🟢 Watchlist JANUARY 13, 2025, Monday. NFA. Those with 🟢 are my top picks

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...

74

30

10

Jaguar8

Jan 13 02:01

NEWS

$Exagen (XGN.US)$
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
Sunday, 12th January at 12:00 pm
New biomarkers on track for commercial launch in January 2025
Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn
CARLSBAD, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:...

2

1

NEWS

$Exagen (XGN.US)$
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

XGN Exagen

Trade Overview

Capital Trend

News

Comments

Market Insights

Latest News

Investment Course

Trump's comeback to the Office

Discussing